Ipsen to acquire Epizyme, expanding its portfolio in oncology
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 9 - Diffuse Largeb Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Diffuse Largeb Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Diffuse Largeb Cell Today - Breaking & Trending Today
AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...
Source: prnewswire.com
DGAP-News: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL Seite 1
22.03.2022 - DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL 22.03.2022 / 21:01 The issuer ... Seite 1
Source: wallstreet-online.de
MorphoSys AG: National Comprehensive Cancer Network Updates Designation of Monjuvi (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)
Source: finanznachrichten.de
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Pre
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous15.03.2022 / 21:01 The issuer is solely responsible for the content of this announcement.Media ReleaseNational Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology...
Source: pharmiweb.com